Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: A Canadian consensus

Stephen Couban, L. Savoie, Y. A. Abou Mourad, B. Leber, M. Minden, R. Turner, V. Palada, N. Shehata, A. Christofides, S. Lachance

科研成果: 期刊稿件文章同行评审

14 引用 (Scopus)
源语言英语
页(从-至)e265-e309
期刊Current Oncology
21
2
DOI
出版状态已出版 - 2014
已对外发布

!!!ASJC Scopus Subject Areas

  • 肿瘤学

指纹

探究 'Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: A Canadian consensus' 的科研主题。它们共同构成独一无二的指纹。

引用此

Couban, S., Savoie, L., Abou Mourad, Y. A., Leber, B., Minden, M., Turner, R., Palada, V., Shehata, N., Christofides, A., & Lachance, S. (2014). Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: A Canadian consensus. Current Oncology, 21(2), e265-e309. https://doi.org/10.3747/co.21.1834